Patent: 10,118,901
✉ Email this page to a colleague
Summary for Patent: 10,118,901
Title: | Therapeutic agents |
Abstract: | The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases. ##STR00001## |
Inventor(s): | Chen; Yu (San Jose, CA), Chen; Yi (Pleasanton, CA) |
Assignee: | Purdue Pharmaceutical Products L.P. (Stamford, CT) |
Application Number: | 14/374,995 |
Patent Claims: | see list of patent claims |
Details for Patent 10,118,901
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2039-02-26 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2039-02-26 |
Bristol-myers Squibb Company | EMPLICITI | elotuzumab | For Injection | 761035 | 11/30/2015 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |